Myelofibrosis
Clinical research in myelofibrosis centers on oral targeted therapy development, with attention to disease control in intermediate and high-risk settings. The sponsor’s work in this area includes evaluation of treatment approaches intended to address marrow fibrosis and related myeloproliferative neoplasm features.
- Targeted therapy for myelofibrosis
- Myeloproliferative neoplasm management
- Intermediate and high-risk disease
Interest extends to combination strategies and symptom-relevant disease modification in patients with persistent hematologic burden.
Acute Leukemia
The sponsor is actively involved in acute leukemia research, including acute myeloid leukemia and related acute leukemias with mixed lineage leukemia rearrangement or NPM1 mutation. This area reflects a focus on genomically defined disease subsets and treatment options for relapsed or refractory disease.
- Acute myeloid leukemia
- Mixed lineage leukemia rearrangement
- NPM1 mutation
Research activity also includes acute leukemia of ambiguous lineage and broader hematologic malignancy settings.
Relapsed and Refractory Hematologic Malignancies
Another major area of interest is treatment development for relapsed and refractory blood cancers, particularly in patients with limited therapeutic options. Trials in this space examine monotherapy and combination approaches aimed at controlling persistent leukemia burden.
- Relapsed/refractory leukemia
- Adult acute leukemia
- Combination therapy
The portfolio includes investigation of agents designed to address biologically distinct leukemia subtypes and treatment-resistant disease.
Neurogenic Detrusor Overactivity
In urology, the sponsor supports research on neurogenic detrusor overactivity in pediatric patients, with attention to urinary symptom control and bladder function. This work includes evaluation in children and adolescents living with neurologic bladder dysfunction.
- Neurogenic detrusor overactivity
- Pediatric urology
- Bladder dysfunction
Associated research also considers patients using clean intermittent catheterization, reflecting interest in functional urinary management.
